Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Icotinib at different
dose levels in combination with whole brain radiotherapy for NSCLC patients with brain
metastases and EGFR mutation.